| Proposed Ticker: AURO | 1290 Hammond Road | |
| Exchange: NASDAQ-National Market | St. Paul, Minnesota 55110 | |
| Industry: Manufacturing | (612) 653-8512 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 6/28/96 | |
| U.S. Shares Filed: | 1,500,000 | Filing Range: | $9.00 - $10.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $14,250,000 | |
| Primary Shares: | 1,500,000 | Expenses: | $260,000 | |
| Secondary Shares: | 0 | Shs Out After: | 5,213,220 | |
| Manager | Tier | Phone |
| John G. Kinnard | Lead Manager | (612) 370-2922 |
| Pennsylvania Merchant Group Ltd | Co-manager | (215) 975-8120 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 5/31/96 | 5/31/95 | 5/31/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $1.51 |
| Net Income: | -$0.52 | -$0.52 | -$0.16 | Liabilities: | $0.19 |
| EPS: | -$0.12 | -$0.12 | -$0.04 | Equity: | $1.32 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Advanced UroScience, Inc. is developing Acyst, an injectable bulking agent, for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency. Stress urinary incontinence is generally defined as the involuntary loss of urine as a result of activities that increase intra-abdominal pressure, such as coughing, laughing, exercising or simply standing up. Acyst is a proprietary composition of pyrolytic carbon coated micro-beads suspended in a carrier gel. Acyst is designed to be injected into the mucosal lining of the urethra at the neck of the bladder through a specially designed needle. The injection procedure involves inserting the needle through a standard cystoscope, allowing the physician to view the bulking of the tissue and the resulting closure of the bladder opening. This minimally invasive outpatient procedure can be accomplished in approximately 30 minutes and is opened to immediately restore the patient to urinary continence. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund human clinical trials, research and development, international sales and marketing and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.